Table 1 Baseline clinicopathological parameters of included patients
From: Differential expression of TIM-3 between primary and metastatic sites in renal cell carcinoma
|  | Paired (N = 83) | Metastatic (N = 80) | P value |
|---|---|---|---|
Age, n (%) | Â | Â | 0.546 |
 < 70 | 76 (91.6) | 71 (88.8) |  |
 ≥ 70 | 7 (8.4) | 9 (11.2) |  |
Gender, n (%) | Â | Â | 0.873 |
 Male | 54 (65.1) | 53 (66.3) |  |
 Female | 29 (34.9) | 27 (33.7) |  |
ISUP, n (%) | Â | Â | 0.066 |
 < 4 | 49 (67.1) | 58 (80.6) |  |
 ≥ 4 | 24 (32.9) | 14 (19.4) |  |
Histological Type, n (%) | Â | Â | 0.032 |
 ccRCC | 59 (71.1) | 68 (61.3) |  |
 Non-ccRCC | 24 (28.9) | 12 (38.7) |  |
Pathology, n (%) | |||
 Sarcomatoid | 6 (19.4) | 2 (28.6) | 0.509 |
 Necrosis | 25 (80.6) | 5 (71.4) | 0.491 |
Nephrectomy, n (%) | Â | Â | 0.001 |
 Yes | 80 (96.4) | 57 (77.0) |  |
 No | 3 (3.6) | 17 (23.0) |  |
ECOG, n (%) | Â | Â | 0.801 |
 0–1 | 53 (70.7) | 59 (76.6) |  |
 ≥ 2 | 22 (29.3) | 18 (23.4) |  |
IMDC, n (%) | Â | Â | 0.293 |
 Low | 14 (18.3) | 19 (28.4) |  |
 Intermediate | 43 (57.3) | 37 (55.2) |  |
 High | 18 (24.0) | 11 (16.4) |  |
T stage, n (%) | Â | Â | 0.587 |
 < 2b | 46 (59.7) | 12 (66.7) |  |
 ≥ 2b | 31 (40.3) | 6 (33.3) |  |
Metastasis, n (%) | |||
 Lung | 6 (8.1) | 17 (28.8) | 0.010 |
 Brain | 7 (9.5) | 12 (20.3) | 0.192 |
 Liver | 1 (1.4) | 2 (3.4) | 0.539 |
 Bone | 18 (24.3) | 22 (37.3) | 0.389 |
 Lymph node | 42 (56.8) | 6 (10.2) | 0.001 |
Treatment, n (%) | |||
 Cytokine | 14 (16.9) | 8 (10.0) | 0.345 |
 Target therapy | 34 (41.0) | 30 (37.5) | 0.882 |
 Radiotherapy | 7 (8.4) | 7 (8.8) | 0.673 |
 Chemotherapy | 3 (3.6) | 5 (6.2) | 0.360 |
Unknown | 25 (30.1) | 30 (37.5) | Â |